<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4896">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532853</url>
  </required_header>
  <id_info>
    <org_study_id>GPRI20103</org_study_id>
    <nct_id>NCT04532853</nct_id>
  </id_info>
  <brief_title>Optimizing Maintenance Therapy in COPD Patients</brief_title>
  <acronym>PIFOTAL</acronym>
  <official_title>Optimizing Maintenance Therapy in COPD Patients: Real-world Observational Study of Peak Inspiratory Flow Rate, Inhalation Technique, and Medication Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Practitioners Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>General Practitioners Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Effectiveness of maintenance therapy for COPD with Dry Powder Inhalers (DPIs)&#xD;
      requires an optimal Peak Inspiratory Flow Rate (PIFR), a proper inhalation technique and&#xD;
      adequate medication adherence from patients. Recent studies have suggested that patients with&#xD;
      reduced peak inspiratory flow may have worse COPD-related symptom burden and increased risk&#xD;
      of COPD-related hospitalizations. However, in primary care, little is known about how many&#xD;
      COPD patients have suboptimal PIFR. Furthermore, there is a paucity of knowledge concerning&#xD;
      the associations of PIFR, inhalation technique and medication adherence with the&#xD;
      effectiveness of maintenance therapy.&#xD;
&#xD;
      Objective: To examine associations of PIFR, inhalation technique, and medication adherence&#xD;
      with health status and disease, exacerbations, and healthcare resource utilization in&#xD;
      patients with COPD receiving maintenance treatment with dry powder inhalers.&#xD;
&#xD;
      Study design: Cross-sectional observational study in five European countries*.&#xD;
&#xD;
      Study population: COPD patients aged 40 years or older who have received COPD maintenance&#xD;
      therapy through DPIs in the past 3 months or longer.&#xD;
&#xD;
      Main study parameters: Health status as measured with the Clinical COPD Questionnaire (CCQ),&#xD;
      COPD Assessment Test (CAT), number of exacerbations, an assessment of PIFR, inhalation&#xD;
      technique errors, medication adherence, healthcare resource utilization (HCRU), medication&#xD;
      use and demographic and clinical covariates.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: No significant burden from participating is expected. Risk of participating is&#xD;
      deemed negligible. In addition, patients may benefit from participating. Specifically,&#xD;
      patients who manifest inhalation errors, will receive a tailored inhalation instruction to&#xD;
      remediate their inhalation errors. The impact of this instruction will not be evaluated in&#xD;
      any way, therefore it should not be seen as an intervention.&#xD;
&#xD;
      * If the preplanned number of patients cannot be included also because of national outbreaks&#xD;
      of SARS-COV-2 resulting in travel restrictions, participation will be sought from researchers&#xD;
      from three other European countries&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">August 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical COPD Questionnaire</measure>
    <time_frame>past 7 days (counted from day of study visit)</time_frame>
    <description>Self reported health status of COPD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD Assessment Test (CAT)</measure>
    <time_frame>past 7 days (counted from day of study visit) [Note that the CAT has no explicit time frame]</time_frame>
    <description>Self reported health status of COPD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbations</measure>
    <time_frame>past 12 months (counted from day of study visit)</time_frame>
    <description>Self reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>past 6 months (counted from day of study visit)</time_frame>
    <description>Of primary care (consultations with GPs and primary care nurse), of secondary care (consultations with registrars or medical specialists in outpatient clinics, emergency departments, rate and duration of hospitalizations, and chest imaging/x-rays), of other healthcare provision (lung function technicians, physiotherapists, dietitians, and psychologists), as well as laboratory assessments and medication use.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1176</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients aged forty years and older and who are treated with DPIs as a maintenance&#xD;
        therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of COPD;&#xD;
&#xD;
          -  Age ≥ 40;&#xD;
&#xD;
          -  Use of maintenance therapy through a DPI in the last 3 months or longer&#xD;
&#xD;
          -  Sufficient investigator-assessed decision-making capacity to provide informed consent&#xD;
             (patients will not be invited if they have acute psychotic disorders, severe pervasive&#xD;
             developmental disorders / severe intellectual disability or advanced neurodegenerative&#xD;
             disease)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An exacerbation in the past 6 weeks (as this requires a patient to recover)&#xD;
&#xD;
          -  Life threatening disease and life expectancy &lt; 6 months (as inclusion of these&#xD;
             patients is unethical)&#xD;
&#xD;
          -  Participation in a randomized clinical trial on COPD medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janwillem Kocks, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Practitioners Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woolcock Institute of Medical Research, University of Sydney</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinthia Bosnic-Anticevich</last_name>
      <phone>+61 414 015 614</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Crete</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioanna Tsiligianni</last_name>
      <phone>+306974424391</phone>
      <email>pdkapa@yahoo.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GPRI</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janwillem Kocks</last_name>
      <phone>+31 (0)50 2113898</phone>
      <email>pifotal@gpri.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radek Gawlik</last_name>
      <phone>+48 601464786</phone>
      <email>radwags@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Health Regional Administration (ARS Centro)</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Correia de Sousa</last_name>
      <phone>+351 253 604800</phone>
      <email>jaimecsousa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ibsalut</name>
      <address>
        <city>Soller</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel R Rodríguez</last_name>
      <phone>0034647982722</phone>
      <email>miguelroman@ibsalut.caib.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD Exacerbations</keyword>
  <keyword>Primary Care</keyword>
  <keyword>Inhalation medication</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Treatment</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

